Bristol-Myers Squibb plans to construct a new large-scale biologics manufacturing facility in Dublin, Ireland to produce multiple therapies for the company’s biologics portfolio. Once completed, the new facility will significantly increase BMS’s biologics manufacturing capacity and play a central role in its global manufacturing network. The company’s portfolio of approved and investigational biologics covers multiple therapeutic areas including oncology, virology and immunoscience.
 
The 30,000-square meter project will house six 15,000-liter bioreactors and a purification area as well as office and lab space. The plant will be built on the grounds of the company’s existing bulk pharmaceutical manufacturing plant and the cost is expected to be comparable to the approximately $900 million investment in the company’s biologics manufacturing facility in Devens, MA.
 
Approximately 350 to 400 scientists, engineers, bioprocess operators, quality specialists and other professionals are expected to work at the facility when operational in 2019.
 
“Our investment in this new facility reflects the strength of our business and the increasingly important role that biologic medicines will play in Bristol-Myers Squibb’s future,” said Lamberto Andreotti, chief executive officer, BMS. “For 50 years, BMS has maintained a significant manufacturing presence in Ireland, and we look forward to building on that legacy through this significant expansion of our manufacturing capability.”